“…Compared to LR-MDS, the clinical management of HR patients significantly differs, in line with the AML approach [2,62,63], aiming at modifying the natural disease history, prolonging survival [80,81], and possibly achieving adequate disease control or cure through allogenic STC, which should be considered early in the disease course and promptly proposed to eligible patients [66][67][68]. HMAs, given with a life-prolonging intent and/or to reduce disease burden for subsequent allogeneic SCT, are still currently the standard of care for patients with HR-MDS [62,63,[103][104][105].…”